Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority …

U Mrowietz, CL Leonardi, G Girolomoni, D Toth… - Journal of the American …, 2015 - Elsevier
Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …
被引用次数：206 相关文章

[引用][C] Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind …

U Mrowietz, CL Leonardi, G Girolomoni… - Journal of the American …, 2015 - cir.nii.ac.jp
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate
to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) …

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority …

U Mrowietz, CL Leonardi, G Girolomoni, D Toth… - Journal of the American …, 2015 - jaad.org
Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority …

U Mrowietz, CL Leonardi, G Girolomoni, D Toth… - 2015 - pubmed.ncbi.nlm.nih.gov
Background Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. Objective We sought to compare a retreatment-as …

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority …

U Mrowietz, CL Leonardi, G Girolomoni… - Journal of the …, 2015 - europepmc.org
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate
to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE) …

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority …

M Ulrich, LL Craig, G Girolomoni, T Darryl… - JOURNAL OF THE …, 2015 - iris.univr.it
BackgroundSecukinumab has demonstrated high, sustained efficacy in psoriasis to 52
weeks on a fixed-interval regimen. ObjectiveWe sought to compare a retreatment-as-needed …

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority …

U Mrowietz, CL Leonardi, G Girolomoni, D Toth… - Journal of the American …, 2015 - infona.pl
Secukinumab has demonstrated high, sustained efficacy in psoriasis to 52 weeks on a fixed-
interval regimen. We sought to compare a retreatment-as-needed versus a fixed-interval …